Rivaroxaban for Treatment of Pediatric Venous Thromb 3 Dose-Exposure-Response Evaluation

Journal of Thrombosis and Haemostasis

18, 1672-1685

DOI: 10.1111/jth.14813

Citation Report

#	Article	IF	Citations
1	Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-Related Venous Thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances, 2020, 4, 4632-4639.	6.3	51
2	Venous Thromboembolism in Children: From Diagnosis to Management. International Journal of Environmental Research and Public Health, 2020, 17, 4993.	4.2	49
3	Direct Oral Anticoagulants: Evidence and Unresolved Issues. Lancet, The, 2020, 396, 1767-1776.	96.9	180
4	Rivaroxaban for the Treatment of Venous Thromboembolism in Pediatric Patients. Expert Review of Cardiovascular Therapy, 2020, 18, 733-741.	2.7	17
5	Review on Characteristics and Analytical Methods of Rivaroxaban. Critical Reviews in Analytical Chemistry, 2022, 52, 865-877.	7.9	24
6	Direct-Acting Oral Anti-Coagulants in Dental Practice: A Retrospective Observational Study (Part 1). Oral Diseases, 2021, 27, 1052-1058.	3.4	4
7	Dabigatran Etexilate and Treatment of Acute Venous Thromboembolism in Children. Lancet Haematology,the, 2021, 8, e2-e3.	14.9	1
8	Evaluation and Management of Coagulopathies and Thrombophilias in Pediatric Patients. Clinics in Laboratory Medicine, 2021, 41, 83-100.	1.9	3
9	Pharmacokinetic Modeling and Simulation Support for Age- and Weight-Adjusted Dosing of Dabigatran Etexilate in Children With Venous Thromboembolism. Journal of Thrombosis and Haemostasis, 2021, 19, 1259-1270.	5.0	17
10	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Pediatric Venous Thromboembolism Treatment and Thromboprophylaxis: A Systematic Review of the Literature. Seminars in Thrombosis and Hemostasis, 2021, 47, 643-653.	4.1	22
11	Direct Oral Anticoagulant Safety During Breastfeeding: A Narrative Review. European Journal of Clinical Pharmacology, 2021, 77, 1465-1471.	3.8	27
12	Thrombosis Prevention and Anticoagulation Management in the Pediatric Patient With Congenital Heart Disease. Cardiology and Therapy, 2021, 10, 325-348.	3.6	36
13	Population Pharmacokinetic Analysis of Rivaroxaban in Children and Comparison to Prospective Physiologically-Based Pharmacokinetic Predictions. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 1195-1207.	3.0	18
14	Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. Journal of Clinical Pharmacology, 2022, 62, 220-231.	2.4	13
15	Safety and Efficacy of Rivaroxaban in Pediatric Cerebral Venous Thrombosis (EINSTEIN-Jr CVT). Blood Advances, 2020, 4, 6250-6258.	6.3	116
16	Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. Journal of Pediatrics, 2022, 240, 14-23.	3.2	6
17	Hemostatic and Thrombotic Disorders in the Pediatric Patient. Blood, 2022, 140, 533-541.	10.6	10
18	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	16

#	Article	IF	Citations
19	National Guidelines on the Management of Venous Thromboembolism: Joint Guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society. Turkish Journal of Thoracic and Cardiovascular Surgery, 2021, 29, 562-576.	0.5	3
20	Direct Oral Anticoagulants for Use in Paediatrics. The Lancet Child and Adolescent Health, 2022, 6, 207-214.	8.0	26
21	Anticoagulation in Pediatric Patients. Hamostaseologie, 2022, 42, 046-053.	1.5	22
22	Clinical Research–When It Matters. Injury, 2023, 54, S35-S38.	2.7	1
23	Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options. Frontiers in Pediatrics, 2022, 10, 855162.	2.4	20
24	Essential Thrombocythemia in Children and Adolescents. Cancers, 2021, 13, 6147.	5.3	21
25	New Anticoagulants in Neonates, Children, and Adolescents. Hamostaseologie, 2022, 42, 123-130.	1.5	6
26	Catheter-Directed Thrombolysis for Massive Deep Vein Thrombosis in an Adolescent With Severe Antithrombin Deficiency. Clinical Case Reports (discontinued), 2022, 10, e05681.	0.8	1
27	Online KidClot Education for Patients and Families Initiating Warfarin Therapy: The eKITE Study. Thrombosis Research, 2022, 215, 14-18.	2.9	6
28	Model-Informed Bridging of Rivaroxaban Doses for Thromboprophylaxis in Pediatric Patients Aged 9 Years and Older With Congenital Heart Disease. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1111-1121.	3.0	8
29	Preparation, Characterization, and Pharmacokinetics of Rivaroxaban Cocrystals With Enhanced in Vitro and in Vivo Properties in Beagle Dogs. International Journal of Pharmaceutics: X, 2022, 4, 100119.	5.6	20
30	Current Evidence for Pharmacologic Therapy Following Stage 1 Palliation for Single Ventricle Congenital Heart Disease. Expert Review of Cardiovascular Therapy, 2022, 20, 627-636.	2.7	1
31	Current Antithrombotic Therapy Strategies in Children With a Focus on Off-Label Direct Oral Anticoagulants—A Narrative Review. Children, 2022, 9, 1093.	3.0	6
32	Rivaroxaban Treatment Among Children With Cancer-Associated Thromboembolism: Real-World Data. Pediatric Blood and Cancer, 2022, 69, e29888.	1.7	12
33	Anticoagulation in Pediatric Cancer–Associated Venous Thromboembolism: A Subgroup Analysis of EINSTEIN-Jr. Blood Advances, 2022, 6, 5821-5828.	6.3	20
34	Direct Oral Anticoagulants Toxicity in Children: An Overview and Practical Guide. Expert Opinion on Drug Safety, 2022, 21, 1183-1192.	3.2	4
35	Intentional Overdose of Rivaroxaban and Alcohol: A Case Report. Pediatric Blood and Cancer, 2023, 70, e29969.	1.7	1
36	Direct Oral Anticoagulants in Pediatric Venous Thromboembolism: Review of Approved Products Rivaroxaban and Dabigatran. Frontiers in Pediatrics, 2022, 10, 1005098.	2.4	10

#	Article	IF	Citations
37	Real World Experience of Efficacy and Safety of Rivaroxaban in Paediatric Venous Thromboembolism. Thrombosis Research, 2023, 221, 92-96.	2.9	19
38	Current Status of Pharmacokinetic Research in Children: A Systematic Review of Clinical Trial Records. Current Reviews in Clinical and Experimental Pharmacology, 2023, 19, 78-92.	2.5	1
39	Just DOAC: Use of Direct-Acting Oral Anticoagulants in Pediatrics. American Journal of Health-System Pharmacy, 2023, 80, 412-422.	1.4	8
40	Evaluation of OpenAI's Large Language Model as a New Tool for Writing Papers in the Field of Thrombosis and Hemostasis. Journal of Thrombosis and Haemostasis, 2023, 21, 1055-1058.	5.0	12
41	Is a Lower Dose of Rivaroxaban Required for Asians? A Systematic Review of a Population Pharmacokinetics and Pharmacodynamics Analysis of Rivaroxaban. Pharmaceutics, 2023, 15, 588.	7.5	25
42	The Value of the Old and the New. Blood Advances, 2023, 7, 3683-3685.	6.3	2
43	What Did We Learn (and Did Not Learn) From the Pediatric Direct Oral Anticoagulant Trials, and How Might We Better Design Pediatric Anticoagulant Trials in the Future?. Research and Practice in Thrombosis and Haemostasis, 2023, 7, 100140.	3.3	12
44	How I Treat Pediatric Venous Thromboembolism in the DOAC Era. Blood, 2024, 143, 389-403.	10.6	25
45	Clinical Impact of a Standardized Risk-Stratified Thromboprophylaxis Protocol for Multisystem Inflammatory Syndrome in Children. Journal of Pediatrics, 2023, 262, 113624.	3.2	4
46	Acute Thrombotic Events in Association With Coronavirus Disease of 2019 Immunization as Initial Presentation of Congenital Factor VII Deficiency. Journal of Pediatric Hematology/Oncology, 2023, 45, e781.	0.9	1
47	Efficacy and Safety of Different Doses of Rivaroxaban and Risk Factors for Bleeding in Elderly Patients With Venous Thromboembolism: A Real-World, Multicenter, Observational, Cohort Study. Advances in Therapy, 2024, 41, 1-22.	5.0	7
48	Real-World Experience With Edoxaban for Anticoagulation in Children at Risk for Coronary Artery Thrombosis. Cardiology in the Young, 2024, 34, 870-875.	0.9	9
49	What's New in Pediatric Critical Care?. Best Practice & Research Clinical Anaesthesiology, 2024, 38, 145-154.	3.4	0
50	Anticoagulation in Pediatric Patients. Techniques in Vascular and Interventional Radiology, 2024, 27, 100958.	1.6	5
51	Systematic Review of Randomized Clinical Trials on Direct Oral Anticoagulants in Pediatric Heart Diseases. Clinical and Applied Thrombosis/Hemostasis, 2024, 30, 10760296241271974.	2.2	8
52	Exposure Matching-Based Pediatric Dose Selection for Drugs With Renal Excretion – Lessons Learned From Pediatric Development of Direct Oral Anticoagulants. Clinical Pharmacology and Therapeutics, 2024, 116, 1174-1187.	5.3	2
53	Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling. International Journal of Molecular Sciences, 2024, 25, 8727.	5.9	39
54	Thrombotic Complications in Pediatric Cancer. Children, 2024, 11, 1096.	3.0	6

#	Article	IF	Citations
55	Unresolved Issues Concerning Venous Thromboembolism. Venous Thromboembolism in Children. Consensus of the French Society of Vascular Medicine (SFMV). JMV-Journal De Medecine Vasculaire, 2024, 49, 211-218.	1.2	0
56	Adverse Events of Factor Xa Inhibitors in Pediatric Patients: A Meta-Analysis and Pharmacovigilance Study. Paediatric Drugs, 2025, 27, 1-16.	4.6	2
57	Trombosi venosa cerebrale associata a otomastoidite con segni di ipertensione endocranica. Medico E Bambino, 2025, 44, 025-031.	0.1	0
58	Interim Results on the Impact of Rivaroxaban Dose Escalation on Recanalisation Time in Paediatric Patients With Venous Thromboembolism. Hamostaseologie, 2025, 45, T-02-12.	1.5	0
59	Extended-Phase Anticoagulant Treatment of Acute Venous Thromboembolism in Children: A Cohort Study From the EINSTEIN-Jr Phase 3 Trial. Lancet Haematology,the, 2025, 12, e357-e364.	14.9	9
60	Thrombotic Aortic Occlusion in Neonates: A Case Report and Review of the Literature. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2025, 3, 100232.	0.9	0
61	Poor-Tasting Pediatric Medicines: Part 1. a Scoping Review of Their Impact on Patient Acceptability, Medication Adherence, and Treatment Outcomes. Frontiers in Drug Delivery, 2025, 5, 1553286.	4.5	29
62	Patterns of Direct Oral Anticoagulant Use in Pediatric Patients: Results From a Multicenter National Database. Pediatric Blood and Cancer, 2025, 72, e31816.	1.7	0
63	Management of Anticoagulant Therapy in Athletes and Sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. Thrombosis and Haemostasis, 2025, 125, 1085-1098.	4.6	4
64	Thrombosis and Thrombophilia. , 2022, .		0
65	Introduction to Venous Thromboembolism and Antithrombotic Drugs. , 2025, .		0
66	Comparison of Rivaroxaban With Warfarin for Intracardiac Thrombosis in the Pediatric Population at Different Cardiac Sites: Early Experience of Anticoagulation Approach and Treatment Outcomes. Thrombosis Research, 2025, 253, 109397.	2.9	3
67	Pediatric Venous Thromboembolism: Considerations for the Interventional Radiologist. Seminars in Interventional Radiology, 2025, 42, 289-302.	1.1	0
68	Effect of Gene Polymorphism on the Pharmacokinetics and Clinical Outcomes of Rivaroxaban: State-of-the-Art Review. Drug Design, Development and Therapy, 2025, 19, 7321-7331.	6.2	5
69	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	0
70	Direct Oral Anticoagulant Rivaroxaban for Secondary Prevention of Catheter-Related Thrombosis in Children With Intestinal Failure: Real-Life Data. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 103231.	3.3	5
71	Rivaroxaban in Chinese Children With Giant Coronary Artery Aneurysms After Kawasaki Disease. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 103211.	3.3	1
72	Considerations of Safety for Women Prescribed Apixaban or Rivaroxaban Who Breastfeed-a Physiologically Based Pharmacokinetic Analysis. Journal of Thrombosis and Haemostasis, 2026, 24, 520-529.	5.0	8

#	Article	IF	Citations
73	Rivaroxaban Versus Warfarin in Pediatric Intracardiac Thrombosis: A Promising Step Forward Amid Methodological Caveats. Thrombosis Research, 2026, 257, 109538.	2.9	0
74	Pharmacokinetic-Driven Individualized Anticoagulation Plan for Pediatric Athletes on Direct Oral Anticoagulants. Pediatric Blood and Cancer, 2026, 73, e70052.	1.7	1
75	2 Cases of Pegylated Asparaginase-Associated Cerebral Venous Sinus Thrombosis in Children: Clinical Analysis and Literature Review. Thrombosis Journal, 2026, 24, 5.	2.9	2
76	Real-World Use of Rivaroxaban for Primary Thromboprophylaxis and Cardiac Thrombosis Treatment in Congenital and Acquired Heart Disease: A Prospective Cohort Study. Scientific Reports, 2026, 16, 13923.	5.2	3
77	Efficacy and Safety of Direct Oral Anticoagulants in Pediatric Patients: A Systematic Review and Meta-Analysis. Frontiers in Public Health, 2026, 14, 1787819.	4.3	0
78	Coagulopathies and Sickle Cell Disease. , 2026, .		0
79	Rare Pediatric Multi-System Thrombosis Post-COVID-19: A Three-Year Follow-Up Case Report and Narrative Review on Rivaroxaban for Long-Term Management. Orphanet Journal of Rare Diseases, 2026, 21, 239.	3.7	0
80	Contemporary Management of Pediatric Venous Thrombosis: How Does It Differ From Adult Care?. Journal of Thrombosis and Haemostasis, 2026, 24, 2755-2765.	5.0	2
81	Rivaroxaban for Extended Anticoagulation of Pediatric Venous Thromboembolism. Translational Pediatrics, 2026, 15, 165.	1.9	0
82	Rivaroxaban for Pediatric Venous Thromboembolism in Routine Clinical Practice: Effectiveness and Safety From a Real-World Cohort. Thrombosis Research, 2026, 263, 109730.	2.9	0
83	Can Edoxaban and Rivaroxaban Be Prescribed for Breastfeeding Mothers? The New Horizons Clinical Trial. Journal of Thrombosis and Haemostasis, 2026, .	5.0	1
84	Neonatal Thromboembolic Disease: Clinical Spectrum and Emerging Evidence for Diagnostic and Therapeutic Strategies Addressing Unmet Needs. Journal of Clinical Medicine, 2026, 15, 6221.	3.8	2
85	Population Pharmacokinetics and Pharmacodynamics Under Treatment Evolution, Time-Varying Covariates, Informative Sampling, and Changing Disease State During Clinical Care. International Journal of Pharmaceutical Research and Allied Sciences, 2025, 14, 102-112.	0.9	0
86	Case Report: Pediatric Deep Vein Thrombosis: When Pain in the Leg Becomes a Telltale Sign. Frontiers in Medicine, 2026, 13, 1909309.	3.7	0
87	Direct Oral Anticoagulants in the Cardiorenal Patient: Pharmacology, Kidney Function Estimation and Dose Selection Across the CKD Spectrum. Current Issues in Molecular Biology, 2026, 48, 1085.	4.3	0